About 15% of BC cases are triple-negative breast cancers (TNBCs), lacking the expression of ERα, PR and HER2-amplification and are thus not responsive to targeted therapies against ERα or HER2. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.